Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
OTX2 antisense RNA 1 (OTX2-AS1) is a long non-coding RNA transcribed from the opposite strand of the OTX2 gene locus, regulated by a common bidirectional promoter with OTX2. It is non-protein coding and is mainly implicated in the regulation of gene expression possibly through RNA-RNA or RNA-protein interactions[6]. OTX2-AS1 is significantly upregulated in several cancer types, particularly medulloblastoma, where it promotes tumor cell growth, viability, and migration. Its expression is also associated with immune infiltration and poorer prognosis in various cancers, including breast cancer, lung squamous cell carcinoma, and gastric cancer[2][3][5]. Notably, OTX2-AS1 upregulation makes medulloblastoma cells more vulnerable to BCL-2 inhibition, suggesting indirect therapeutic implications[3].
Not direct drug targeting; BCL-2 inhibition suppresses growth of OTX2-AS1 overexpressing medulloblastoma cells[3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on OTX2 antisense RNA 1 (OTX2-AS1).